Daiichi-Sankyo, GSK Venture Vows 14 Vaccines, Third Of Japan Market
This article was originally published in PharmAsia News
Executive Summary
Japan Vaccine, a venture vaccine maker started by Daiichi-Sankyo and GlaxoSmithKline, officially began business with a vow to market 14 drugs with a view at eventually owning a third of Japan's market.